Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eminence Opens GMP Cell Culture Media Manufacturing Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Eminence Opens GMP Cell Culture Media Manufacturing Facility

Aims to address the rapidly growing demand for high-quality media in the fields of vaccines, gene, cell therapies, antibodies, and recombinant proteins.

By: Anthony Vecchione

Eminence Biotechnology Co., Ltd. reported that its state-of-the-art facility for the commercial production of cell culture media is fully operational. The opening aims to address the rapidly growing demand for high-quality media in the fields of vaccines, gene therapies, cell therapies, antibodies, and recombinant proteins.

The new facility, at the BIOBAY Phase II, Suzhou Industrial Park, occupies approximately 7,000 square meters and comprises dedicated zones for media production, warehousing, and laboratory functions. With three dry powder production lines and two liquid production lines, the facility has an annual output of up to 20 million liters of dry powder media and 300,000 liters of liquid media.

The new facility adheres to international GMP standards, ISO9001, and ISO13485 regulations. It is designed to provide biopharmaceutical companies worldwide with consistently high-quality, batch-to-batch stable cell culture media products.

Frank Song, Chairman and CEO of Eminence, said, “From the very beginning, our focus has been firmly set on the field of cell culture media. After over seven years of growth, our factory in Changzhou has reached its capacity, and this new facility was designed leveraging the operational experience from Changzhou and integrating it with more advanced large-scale pin-milling technology to standardize production processes, ensuring stable and continuous production.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics